Positron Corporation Sees Significant Opportunities in Canadian PET Market with Ontario’s Approval of PET
INDIANAPOLIS-(Business Wire)-September 14, 2009 - Positron Corporation (OTCBB:POSC) today announced that the Ministry of Health and Long Term Care of Ontario, Canada is making positron emission tomography (PET) scanning a publicly insured health service available to cancer and cardiac patients under conditions where PET scans have been proven to be clinically effective. The Ministry of Health and Long Term Care (MOHLTC) has adopted an evidence-based approach to the introduction of PET imaging in the province for certain cancer and cardiac indications.
Joe Oliverio, Chief Technical Officer of Positron said, “Ontario, the largest province in Canada, introducing PET into their health system represents a significant opportunity for Positron to offer a cost effective general purpose scanner into a large socialized network. We believe that the market for Positron’s Attrius PET scanner is potentially hundreds of units in a relatively short period of time. Health Canada’s approval of PET is further evidence that PET is the future of nuclear medicine. Positron plans to focus on marketing and selling its PET product throughout all Canadian provinces and estimates the entire market potential to be approximately 1,000 scanners.”
About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution. Positron products include: the Attrius™, a PET imaging device; the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assist™, a radiopharmaceutical injection shield. More information about Positron is available at www.positron.com.
Forward Looking Statements: This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.
For further information please contact Positron Corporation at (317)576-0183
 |
 |
 |
|
||
 |
|
 |
|
||
Search Our News Using Google Search
Can't find what you want? Try using Google:
